Announcement PDF ASX Announcement 08/03/2021 Emyria CEO in multiple webinars, Wednesday 10th March Emyria Limited (ASX: EMD) (Emyria or the Company), is pleased to invite shareholders, investors, media and interested parties to hear Emyria Managing Director and CEO, Dr Michael Winlo, speak at the following webinars this Wednesday 10 March 2021 Broker Briefing Investor Webinar: Will feature video presentations from four ASX-listed technology stocks. Date: 10 March 2021 Time: 11:30am (AEDT) / 8:30am (WST) Registration: http://brokerbriefing.com/digitalevent Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand to info@brokerbriefing.com Mind Medicine Australia: Why med-tech firms, venture capitalists and bankers are investing in psychedelic medicine. Global interest and investment in psychedelic medicine companies is accelerating. However, these treatments are not like typical medicines. The patient experience and clinical care model is intense and also deeply, and necessarily, intertwined. So, the question arises, how can we develop care delivery models for these treatments that are safe, effective but also commercially viable? We will explore these themes and learn from Emyria’s experience creating an evidence-generating care model for medicinal cannabis. Date: 10 March 2021 Time: 7:25pm for 7:30pm start – 8:45pm (incl Q&A) (AEDT) Registration: https://buff.ly/3hUMThn Following the presentation there will be a Q & A panel with Peter Hunt AM, Chairman and Co-founder of Mind Medicine Australia, Dr Michael Winlo, Managing Director of Emyria and Professor Alistair Vickery, Executive Medical Director of Emyria. This announcement has been approved and authorised for release by the Managing Director of Emyria Limited. 1 For further information: Dr Michael Winlo Managing Director (08) 6559 2800 mwinlo@emyria.com Lexi O’Halloran Media/Investor Relations + 61 (0) 404 577 076 lexi@janemorganmanagement.com.au Andrew Williams Media Relations +61 (0) 412 614 125 andreww@profilemedia.com.au About Emyria (www.emyria.com) Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services (Emerald Clinics - www.emeraldclinics.com.au) Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. 2